Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melanie Grant

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Blood Advances|January 4, 2018
Developing T-cell therapies for lymphoma without receptor engineeringMelanie Grant, Catherine M Bollard
Hematology. American Society of Hematology. Education Program|December 10, 2017
Developing T-cell therapies for lymphoma without receptor engineeringMelanie Grant, Catherine M Bollard
Nature Communications|November 19, 2021
Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumorsSamuel Rivero-Hinojosa, Melanie Grant, Aswini Panigrahi, et al.
Molecular Therapy. Methods & Clinical Development|November 14, 2019
HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing PlatformShabnum Patel, Ryo Hanajiri, Melanie Grant, et al.
Frontiers in Immunology|April 16, 2019
Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency DisordersShabnum Patel, Haili Lang, Gelina Sani, et al.
Cytotherapy|April 9, 2021
Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapiesMaja Stanojevic, Amy B Hont, Ashley Geiger, et al.
Blood Advances|September 8, 2021
Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphomaHema Dave, Madeline Terpilowski, Mimi Mai, et al.
Blood Advances|March 4, 2022
Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMTHannah Kinoshita, Kenneth R Cooke, Melanie Grant, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Blood Advances|January 4, 2018
Developing T-cell therapies for lymphoma without receptor engineeringMelanie Grant, Catherine M Bollard
Hematology. American Society of Hematology. Education Program|December 10, 2017
Developing T-cell therapies for lymphoma without receptor engineeringMelanie Grant, Catherine M Bollard
Nature Communications|November 19, 2021
Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumorsSamuel Rivero-Hinojosa, Melanie Grant, Aswini Panigrahi, et al.
Molecular Therapy. Methods & Clinical Development|November 14, 2019
HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing PlatformShabnum Patel, Ryo Hanajiri, Melanie Grant, et al.
Frontiers in Immunology|April 16, 2019
Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency DisordersShabnum Patel, Haili Lang, Gelina Sani, et al.
Cytotherapy|April 9, 2021
Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapiesMaja Stanojevic, Amy B Hont, Ashley Geiger, et al.
Blood Advances|September 8, 2021
Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphomaHema Dave, Madeline Terpilowski, Mimi Mai, et al.
Blood Advances|March 4, 2022
Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMTHannah Kinoshita, Kenneth R Cooke, Melanie Grant, et al.
Pageof 1